Tempero Bio has hit the brakes on…
Tempero Bio has hit the brakes on a phase 2-stage [...]
Tempero Bio has hit the brakes on a phase 2-stage [...]
FDA is said to be making a U-turn on uniQure’s [...]
Roche may have been exploring ways to shuttle drugs to [...]
Welcome to the Fierce Biotech Graveyard, our annual ritual remembering [...]
Nanobiotix is continuing to find fresh ways to eke money [...]
4DMT has sold the Asia-Pacific rights to its eye gene [...]
Gilead has chosen a partner for lenacapavir in the race [...]
Steven Hatfill, a senior advisor for biosecurity at the Department [...]
Eli Lilly has halted development of a phase 2 P2X7 [...]
Bristol Myers Squibb is shedding two clinical programs from its [...]